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Abstract: Occupational and environmental exposure to cadmium is associated with the
development of urothelial cancer. The metallothionein (MT) family of genes encodes proteins
that sequester metal ions and modulate physiological processes, including zinc homeostasis. Little
is known about the selectivity of expression of the different MT isoforms. Here, we examined
the effect of cadmium exposure on MT gene and isoform expression by normal human urothelial
(NHU) cell cultures. Baseline and cadmium-induced MT gene expression was characterized by
next-generation sequencing and RT-PCR; protein expression was assessed by Western blotting using
isoform-specific antibodies. Expression of the zinc transporter-1 (SLC30A1) gene was also assessed.
NHU cells displayed transcription ofMT-2A, but neitherMT-3 norMT-4 genes. Most striking was a
highly inducer-specific expression of MT-1 genes, with cadmium inducing transcription ofMT-1A,
MT-1G,MT-1H, andMT-1M. WhereasMT-1Gwas also induced by zinc and nickel ions andMT-1H by
iron, bothMT-1A andMT-1M were highly cadmium-specific, which was confirmed for protein using
isoform-specific antibodies. Protein but not transcript endured post-exposure, probably reflecting
sequestration. SLC30A1 transcription was also affected by cadmium ion exposure, potentially
reflecting perturbation of intracellular zinc homeostasis. We conclude that human urothelium displays
a highly inductive profile of MT-1 gene expression, with two isoforms identified as highly specific to
cadmium, providing candidate transcript and long-lived protein biomarkers of cadmium exposure.
Keywords: Metallothionein; urothelium; urothelial cancer; cadmium exposure; zinc transporter
1. Introduction
Occupational and environmental exposure to cadmium has increased as a result of the burning of
fossil fuels and widespread use of the “heavy” metal in anthropological activities, such as battery
production, electroplating, smelting, and soldering (reviewed [1]). Cadmium ions accumulate
in the body in an almost irreversible manner [2], as the metal cannot be metabolized to a less
toxic species [3] and has a low excretion rate [4]. This low excretion rate is thought to be
due to intracellular sequestration of cadmium ions by metal-binding proteins [5–7]. An association
between cadmium exposure and bladder (urothelial) carcinogenesis has been reported, with higher
cadmium concentrations demonstrated in the blood [8] and urine [9–11] of patients with bladder
cancer. In vitro research supports these correlative studies, with malignant transformation of the
Int. J. Mol. Sci. 2019, 20, 1344; doi:10.3390/ijms20061344 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 1344 2 of 18
immortalized RWPE-1, TLR1215, 16HBE, and UROtsa cell lines reported after extended chronic
cadmium exposure [12–15]. The bladder stores concentrated urine prior to voiding, meaning that
the urothelial lining of the bladder (which functions as one of the tightest epithelial barriers [16]) is
potentially exposed to excreted xenobiotics [16–18]. It is currently not known whether exposure to
urinary cadmium is limited by the presence of an intact urinary barrier.
The metallothioneins (MTs) are a superfamily of low-molecular weight (~6 kDa), cysteine-rich
proteins that are induced by and bind a range of metal ions, including cadmium [19,20]. Through
this sequestration of metal ions MTs are considered to play a primary role in metal detoxification [21,22],
but also metal (e.g., zinc) homeostasis [23–25] and the scavenging of reactive oxygen species
(ROS) [26,27]. MT involvement in the bodily response to cadmium exposure has beenwell-documented,
with numerous studies demonstrating cadmium-induced MT expression both in vitro [28–34] and
in vivo [35,36].
Direct binding of MT protein to cadmium ions [37,38] results in a MT-cadmium complex that is
highly resistant to degradation [5–7]. In humans, four main MT subfamilies exist (MT-1, MT-2/2A,
MT-3, and MT-4), with MT-1 consisting of nine isoforms (-A, -B, -E, -F, -G, -H, -L, -M, and -X) [39] each
encoded on individual genes. It is predicted that the individual MT isoforms have distinct properties
including structure [40,41], tissue- and inducer-specific expression [22,34,42–47], induction rate [48],
translational efficiency [41], and degradation rate [49,50]. Cadmium is reported to be the most potent
inducer of MT expression [51]. This offers the potential that individual MT isoforms may be utilized as
specific biomarkers of human exposure to cadmium, although it remains unclear which isoform(s)
are responsible for cadmium sequestration. This lack of discrimination is largely due to the high
homology between isoforms and the lack of discriminatory reagents, with no validated antibodies able
to distinguish MT-1 and MT-2 subfamilies, nor the different MT-1 isoforms [41,52].
MTs are reported to work cooperatively with zinc transporters to regulate cellular zinc
homeostasis, potentially by modulating cellular zinc ion concentration [39], although the exact
mechanisms are unknown. Thus, a possible consequence of exposure to cadmium ions may be
altered cellular zinc homeostasis. Cadmium and zinc possess highly similar properties, and it has been
shown that cadmium can substitute for zinc in biological systems [53]. This can disrupt the normal
functioning of various biological pathways [54,55], thus indirectly influencing processes involved in
carcinogenesis such as cell proliferation and metastasis [56].
Our aims were to investigate MT isoform expression and specificity of induction in human
urothelium under baseline and cadmium-exposed conditions, using a well-characterized normal
human urothelial (NHU) cell culture system that includes polarized differentiated NHU cell sheets
possessing tight barrier function [57,58]. Prior to cadmium exposure, cellular growth assays were
performed to assess cytotoxicity. Next, we exposed NHU cells to a variety of potential MT inducers,
including reactive oxygen species (ROS) [59,60], essential metals [44,61–66], and heavymetals [67–70] to
define the specificity of response. Previously unpublished MT-1 isoform-specific antibodies were used
to discriminate between MT-1 isoform proteins. Lastly, we determined whether transcription of the
free zinc efflux regulator zinc transporter-1 (SLC30A1) [71] was altered as a consequence of cadmium
exposure. The results revealed that MT isoform expression was inducer-specific, and that abundance of
both MT-1A and MT-1M transcript and protein was highly cadmium-specific, highlighting their
potential as biomarkers of exposure. Cadmium was able to penetrate an intact urothelial barrier and
effected transcriptional upregulation of SLC30A1, indicating a potential route for cadmium uptake and
possible subsequent substitution in zinc homeostatic mechanisms.
2. Results
2.1. Influence of Cadmium on NHU Cell Culture Growth and Uptake of Cadmium across an Intact
Urothelial Barrier
Exposure of nondifferentiated NHU cells to cadmium revealed that cell growth was unaffected
by concentrations ≤ 10 µM CdCl2 whilst exposure to 20 µM CdCl2 resulted in distinct cytotoxicity
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(Figure 1A). Replication in a second independent cell line confirmed that exposure to 10 µM CdCl2
did not affect NHU cell growth (Figure 1B); this concentration was therefore selected for further
experiments. When differentiated NHU cell cultures (three independent cell lines) were grown on
permeable membranes in triplicate and exposed apically to 10 µM CdCl2 for 72 h, no effect was seen
on barrier function (control versus cadmium-exposed transepithelial electrical resistance (TEER) of
3.24 ± 0.48 kΩ.cm2 versus 3.17 ± 0.52 kΩ.cm2, mean ± SEM; p = 0.93; Table S1). The barrier was
retained during CdCl2 exposures of at least seven days, over which time the TEER increased in the
cadmium-exposed culture to 1.8-fold over control. Analysis of cell lysates by inductively coupled
plasma optical emission spectroscopy (ICP-OES) revealed an intracellular cadmium concentration of
0.94 µM in lysates from cadmium-exposed cultures compared to 0.08 µM for control cultures.
̛ ̛
Figure 1. Biomass growth assays for in vitro normal human urothelial (NHU) cell cultures exposed
to cadmium. AlamarBlue® assays were performed over 7 days on NHU cell cultures seeded at
6 × 104 cells/cm2. (A) NHU cells were exposed to a range of cadmium concentrations from 0
to 20 µM (n = 1 independent cell line). Each data point represents mean percentage reduction in
AlamarBlue® ± S.D. from three replicate cultures. (B) NHU cells were exposed to 10 µM CdCl2 for
up to 7 days. Data points represent mean percentage reduction in AlamarBlue® ± S.D. from two
independent NHU cell lines, each performed in triplicate.
2.2. Baseline and Cadmium-Induced MT Transcription in NHU Cells
NHU cells maintained in culture in nondifferentiated and differentiated states were examined for
baseline expression of MT genes. Analysis by mRNA-seq of nondifferentiated NHU cells revealed high
expression ofMT-1E andMT-1X and low expression ofMT-1A,MT-1B,MT-1F, andMT-1G; there was
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no detection ofMT-1H orMT-1M transcripts (Figure 2A).MT-2A expression was three times greater
than all the MT-1 genes combined. No expression was detected forMT-3 orMT-4. In almost all cases
where MT gene expression was detected in nondifferentiated NHU cells, the expression was reduced
in the differentiated state. This was most striking forMT-2A (log2FC = 4.2; q = 4.08 × 10
−3) andMT-1E
(log2FC = 1.5; q = 4.0 × 10
−4), although between-donor variation prohibited statistical significance
for many genes with lower expression. The apparent exception was MT-1X, where the average
expression increased in the differentiated state. However, this was inconsistent between donors, and
the differential expression was nonsignificant. Interestingly,MT-1L (which generates a transcript with
a premature stop codon [72]) was expressed at similar abundance toMT-1E in the nondifferentiated
cells, but with a much greater downregulation in the differentiated state (log2FC = 5.4; q = 8.4 × 10
−4).
Previous reports of a truncation-rescuing polymorphism [73] was not identified in these donors,
so whileMT-1L is unlikely to form a functional protein, it may play a role in MT-1 transcript regulation.
Expression was detected for SLC30A1 in both nondifferentiated and differentiated states (Figure 2A),
but there was no significant differentiation-associated change in expression.
 
Figure 2. Baseline and cadmium-induced MT transcript expression by NHU cells in vitro.
(A) Next-generation sequencing data showing baseline MT isoform transcription in nondifferentiated
and differentiated NHU cells (n = 3 independent cell lines; standard deviation is shown). (B,C) MT
gene expression in NHU cells assessed by RT-PCR. The total cDNA input was 1 µg and PCR reaction
products were removed after 25 cycles; GAPDH was included as input control. See Table 1 for primer
sequences and product sizes. Note that medium was changed at time T = 0 only and there was no
renewal of cadmium over the period. The figure shows results representative of n = 3 independent
NHU cell lines. Additional PCR controls included genomic DNA as a positive control and a no-template
(H2O) negative control; RT negative samples confirmed absence of genomic contamination. In (B),
the result of exposing nondifferentiated NHU cells to different concentrations of cadmium (0–20 µM)
for 72 h on MT gene expression is shown. In (C), MT gene expression is shown in differentiated NHU
cell cultures following exposure to 10 µM CdCl2 for up to 72 h.
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RT-PCR results supported the NGS data, although the variability in transcript detection in
nondifferentiated NHU cells indicated a potentially inducible state (Figure 2B). Differentiated NHU
cell cultures revealed a more consistent baseline expression of several MT-1 genes, particularlyMT-1X
(Figure 2C).
Exposure to cadmium ions caused a massive induction of all eight MT-1 genes (MT-1A,MT-1B,
MT-1E,MT-1F,MT-1G,MT-1H,MT-1M, andMT-1X) within 12 h of initial exposure, as demonstrated
by the RT-PCR results, with expression receding over time (Figure 2B,C). Whereas expression of
MT-1 transcripts was mostly lost after 48 h of continuous cadmium exposure in nondifferentiated
cell cultures (Figure 2B with independent cell line repeats in supplementary Figures S1 and S2), MT-1
subfamily transcript expression was still detectable in differentiated cell cultures after 72 h exposure
(Figure 2C; with independent repeats in supplementary Figures S3 and S4).
Irrespective of differentiation state and the presence or absence of cadmium,MT-2A transcript
expression was constitutively high, whilst MT-3 and MT-4 transcripts were invariably absent.
Based on this, theMT-2A,MT-3, andMT-4 genes were not further studied. By contrast, the strong
induction of theMT-1A, -1G, -1H, and -1M paralogs, whichwas consistent following cadmium exposure
in three independent NHU cell lines, was further investigated for specificity. As the RT-PCR results
demonstrated a striking on/off transcriptional response of these MT-1 isoforms to cadmium exposure,
it was decided to continue with this approach, as quantitative PCR would not have added anything to
the data.
2.3. Specificity of Cadmium-Induced MT Transcription
NHU cell cultures were exposed to a variety of candidate MT inducers identified from
the literature.
ROS is reported as a by-product of cadmium exposure [59], and therefore we sought to determine
the effects of ROS on transcription of MT-1 genes. The ROS-inducing agent sulforaphane (C6H11NOS2)
and ROS-inhibitor ascorbic acid (C6H8O6) were titrated against transcription of the ROS-sensitive
heme oxygenase-1 (HMOX1) gene [74,75] to infer intracellular ROS activity (Figure 3A,B, respectively).
Induction of expression of the four MT-1 genes in response to cadmium exposure was unaffected by
25 µg/mL ascorbic acid used to inhibit ROS, suggesting that ROS was not responsible (Figure 3C).
This conclusion was supported by the failure of 5 µM sulforaphane to induceMT-1 expression (replicate
in supplementary material, Figure S5).
Differential induction of MT-1 paralogs was examined in response to other metal ions,
both essential and carcinogenic (replicates in supplementary material, Figures S6 and S7). Both zinc
and nickel exposure inducedMT-1G transcription, whereasMT-1H transcript expression was only
minimally induced by zinc, and nickel had no effect. MT-1A transcription was constitutively low under
all conditions apart from cadmium exposure, which increased expression, andMT-1M transcription
was highly induced by exposure to cadmium alone.
Figure 3. Cont.
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Figure 3. Specificity of metallothionein (MT) transcription induction by cadmium. MT gene expression
was assessed by RT-PCR in NHU cells exposed to a variety of candidate inducers. The total cDNA
input was 1 µg and PCR reaction products were removed after 25 cycles; GAPDHwas included as input
control. Note that medium was changed at time T = 0 only and there was no renewal of treatments over
the period. Additional PCR controls included genomic DNA as a positive control and a no-template
(H2O) negative control; RT negative samples confirmed absence of genomic contamination. In (A),
nondifferentiated NHU cell cultures were treated with a range of concentrations of sulforaphane
(C6H11NOS2) for 12 h, and the effect on transcription of the ROS-sensitive gene HMOX1 assessed
in comparison to exposure to 10 µM CdCl2 (n = 1 independent cell line). The concentration of
C6H11NOS2 that induced transcription of HMOX1 to a comparable extent to cadmium was selected.
In (B), nondifferentiated NHU cell cultures were treated with a range of concentrations of ascorbic acid
(C6H8O6) for 12 h in combination with 10 µM CdCl2 and the effect on HMOX1 transcription assessed.
The concentration of C6H8O6 that caused the biggest decrease in HMOX1 transcription was selected.
In (C), NHU cell cultures (n = 2 independent cell lines) were exposed to a range of candidate regulators
and transcript expressionwas assessed for theMT-1 genes shown above to bemost sensitive to cadmium
induction (from Figure 2B,C). Candidate inducers tested were cadmium (10 µM CdCl2), cadmium
combined with ascorbic acid (10 µM CdCl2 + 25 µg/mL C6H8O6), copper (10 µM CuSO4), iron (10 µM
FeSO4), zinc (10 µM ZnCl2), arsenite (2 µMNaAsO2), nickel (200 µMNiCl2), and sulforaphane (5 µM
C6H11NOS2). Essential metals were applied at equivalent concentrations to cadmium. Arsenite and
nickel were both used at their highest noncytotoxic concentrations based on initial titration experiments
(not shown).
2.4. Immunoblotting With Isoform-Specific Antibodies
To examine if the observed induction of MT-1 gene expression translated to protein, antibodies
specific to the MT-1A and MT-1M isoforms were used to perform Western blotting. Control
nondifferentiated NHU cells lacked MT-1A and MT-1M protein expression (Figure 4A). Cadmium
exposure caused induction of both MT-1A and MT-1M proteins after 72 h (replicate in supplementary
material, Figure S8). Both proteins were also induced in cadmium-exposed differentiated NHU cells
(Figure 4B; replicated in supplementary material, Figure S9).
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Figure 4. Western blot detection of cadmium-induced MT-1A and MT-1M expression in NHU cells
using subtype-specific antibodies. MT-1A and MT-1M protein induction was observed by Western
blotting of NHU cells exposed to 10 µMCdCl2 for 72 h. Total protein input was 20 µg per track, with
β-actin expression used to verify equal protein loading. Figures show western blots probed with
MT-1A and MT-1M isoform-specific antibodies in (A) nondifferentiated and (B) differentiated NHU
cell cultures exposed to cadmium for 72 h (representative blots shown from n = 3 independent cell
lines). In (B), differentiated barrier formation was confirmed by TEER (see Figure 3B). (C) Western blot
showing specificity of MT-1A and MT-1M protein induction (representative of n = 2 independent cell
lines tested). Proliferating NHU cells were exposed to a range of potential inducers for 72 h and protein
expression assessed. The candidate inducers tested were cadmium (10 µM CdCl2), copper (10 µM
CuSO4), iron (10 µM FeSO4), zinc (10 µM ZnCl2), arsenite (2 µMNaAsO2), nickel (200 µMNiCl2), and
sulforaphane (5 µM C6H11NOS2). MT-1A protein expression is reported as fold-change relative to
unexposed control cells.
The specificity of MT-1A and MT-1M protein induction was examined in response to the wider
range of candidate inducers. Western blotting revealed that the MT-1M isoform was induced only by
cadmium exposure, supporting the RT-PCR results (Figure 4C; replicated in supplementary material,
Figure S10). MT-1A protein expression was highly induced by cadmium exposure, although low
protein expression was observed under other conditions. As assessed by densitometry, only cadmium
was capable of increasing MT-1A protein expression over control, resulting in a ~6-fold increase in
MT-1A protein expression (Figure 4D).
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2.5. Upregulation of Zinc Transporter-1 (SLC30A1) Transcription in Cadmium-Exposed NHU Cells
RT-PCR of both nondifferentiated and differentiated NHU cells revealed that cadmium
exposure resulted in increased SLC30A1 gene transcription compared to unexposed controls
(Figure 5A; replicated in supplementary material, Figure S11). After cessation of exposure, SLC30A1
transcript expression receded over time, and this decrease was observed to occur most rapidly
in nondifferentiated (after 24 h; Figure 3B) compared to differentiated (after 11 days; Figure 5C)
cell cultures.
 
̛
Figure 5. Cadmium induction of zinc transporter-1 (SLC30A1) gene transcription. SLC30A1 gene
transcript expression was assessed by RT-PCR, with PCR reaction products removed after 25 cycles.
PCR controls included genomic DNA as a positive control and a no-template (H2O) negative control.
Total cDNA input was 1 µg with GAPDH used as an input loading control; RT-ve samples confirmed
the absence of genomic contamination. For differentiated NHU cells, differentiation was confirmed
by assessment of TEER as >1000 Ω.cm2 (see supplementary materials, Table S1). (A) NHU cells in
nondifferentiated and differentiated states were maintained in control medium or with 10 µMCdCl2
for up to 72 h. Note that medium was changed at time T = 0 and there was no renewal of the cadmium
over the period. The figure shows representative results from n = 3 (nondifferentiated) and n = 1
(differentiated) independent NHU cell lines. (B) RT-PCR of NHU cells in a nondifferentiated state
maintained in standard medium (control) or with 10 µM CdCl2 for up to 24 h prior to the experiment
(‘pre-exposure’), whereupon cadmium was removed from the medium (time point 0) and culture
continued for a further 48 h. (C) RT-PCR of NHU cells in a differentiated state maintained in standard
medium (control) or with 10 µM CdCl2 for up to 3 days prior to the experiment (‘pre-exposure’),
whereupon cadmium was removed from the medium (time point 0) and culture continued for up to
11 days.
3. Discussion
To the best of the authors’ knowledge, this is the first study to investigate if cadmium exposure
affects urothelial tight barrier function. Previous studies have examined the effect of cadmium exposure
on renal [76] and bronchial [77] epithelia, with both studies reporting a decrease or complete collapse of
barrier function. By contrast, the results from this study showed that urothelial barrier function was
retained and even tightened. This may reflect the type of epithelium being tested, as urothelial cells
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are known to form one of the tightest epithelial barriers in the human body and thus may be unique
in their resistance to cadmium. Although cadmium did not compromise urothelial barrier function,
our results found that apical exposure induced expression of MT-1 isoforms in underlying NHU cells
and using ICP-OES, cadmium was directly detected in differentiated urothelial cell sheets. Taken
together, these results indicate that the urothelium remains intact and may even mount a protective
response to cadmium in terms of tight junction tightening, yet the heavy metal is still able to penetrate
the urothelial barrier.
Also for the first time, we describe specific MT gene expression by normal human urothelium.
Our results are consistent with previous reports in other tissues that MT-1 is the inducible
subfamily [22,40,78] whereas MT-2A is the most widely expressed isoform, accounting for up to
50 % total MT expression in humans [6,79]. In agreement with the consensus that MT-3 is
neural-restricted [80], we found no baseline expression and no agents that could induce MT-3
transcription in urothelial cells. As an anomaly, one group has previously suggested a link between
heavy metal exposure, MT-3 induction, and urothelial carcinogenesis based on high MT-3 expression
in malignant bladder cancer [81]. This group further supported their findings using in vitro studies in
cadmium-transformed UROtsa cells [82,83]. However, we were not able to replicate those findings in
our normal cell system.
Of the MT-1 gene family, transcription of MT-1F and MT-1G has previously been described
as constitutive in human umbilical vein epithelial cells (HUVEC) under baseline conditions [42].
Both these genes exhibited low basal but inducible expression in NHU cells, therefore it cannot be
certain whether the expression differences between tissues are constitutive, or perhaps due to inducers
present in the culture medium. Whereas we found the majority of MT-1 gene paralogs to be inducible
by cadmium exposure, transcript expression was transient, presumably due to sequestration leaving
fewer free cadmium ions to maintain induction. By contrast, expression of MT-1 proteins was more
stable and in line with the sequestering nature of the formed MT-cadmium complex. Previously, MT-1
protein isoform detection has been performed using mass spectrometry [41], but the demonstrated
availability of specific antibodies now opens the door to detection using immunochemical approaches.
Exposure of proliferating NHU cell cultures to a range of divalent metal ions revealed
differential and inducer-specific induction of MT-1 isoforms. For example, zinc ions induced
strong transcription ofMT-1G, but notMT-1A genes, whereas nickel ions causedMT-1G expression
exclusively. Inducer-specific expression of MT-1 genes has been noted in other cell types [34,44–47],
supporting the hypothesis that individual isoforms have very selective metal ion sequestering
functions [5,6,22,39,40,84]. Western blotting revealed that cadmium was the most potent inducer of
MT-1A protein expression, whereas MT-1M protein expression was highly specific to cadmium,
revealing the potential of both as biomarkers of cadmium exposure. Neither arsenic nor nickel
induced MT-1A or MT-1M protein expression, further demonstrating the specificity of MT-1 isoforms
to differentiate between different nongenotoxic carcinogenic metals [85,86].
Alongside a pathophysiological role in sequestering carcinogenic metals, the MTs are considered
to contribute to the normal homeostasis of zinc, which as a cofactor involved in many key cellular
processes [56] is under tight control. MT sequestration and zinc transporter efflux coordinated by a
common transcription factorMTF-1 [87] is thought to regulate the availability of zinc [88–91]. Changes
in intracellular zinc concentration have been associated with tumor growth and progression [92].
The displacement of zinc from the proteome by cadmium may affect the intracellular concentration
and/or availability of zinc ions and can substitute and destabilize the functional sites of zinc-containing
proteins, such as zinc-finger transcription factors, changing the character and/or rendering them
nonfunctional [54,55].
Preliminary investigation into the effect of cadmium exposure on zinc homeostasis in normal
urothelial cells revealed an upregulation of the zinc transporter-1 (SLC30A1) gene transcript in
nondifferentiated NHU cells. SLC30A1 upregulation was also observed in cadmium-exposed
differentiated NHU cell sheets possessing a functional barrier, further suggesting that cadmium can
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penetrate an intact urothelial barrier. Our results agree with a previous study using the human hepatic
HepG2 cell line, which demonstrated increased SLC30A1 protein expression and localization at the cell
membrane after acute cadmium exposure [93]. A later study showed cadmium exposure resulted in a
93% increase in the intracellular labile zinc concentration, suggesting a large displacement of zinc ions
from the proteome, possibly due to substitution by cadmium [94].
MT expression is often seen as a ‘double-edged sword’, as on the one hand it functions to
protect the cell, but by the same mechanisms can also facilitate malignant events [6,22,95,96]. MTs may
contribute to cell survival by increasing resistance to ROS-induced apoptosis [97] and increasing cellular
proliferation [32]. Cadmium exposure can result in inhibition of DNA repair [98], which coupled
with increased cellular protection via cadmium-induced MT expression, increases the probability of
deleterious cells surviving and passing on defects to their progeny [96]. The ability of MT to counteract
ROS could also play a role in chemotherapy resistance, and high expression of MT has been correlated
with treatment resistance in bladder cancer [99,100]. Specifically, after radical surgery and adjuvant
chemotherapy 100% patients with high tumor MT expression progressed within nine months, whereas
in patients with low MT expression only 65% had progressed after five years [101].
Our study supports a concordant induction of MT isoforms and SLC30A1 transcription in response
to cadmium exposure. Whereas this does not directly contradict hypotheses that cadmium exposure
increases cellular zinc concentration or that cellular zinc homeostasis is maintained through the
cooperative regulation of MT and zinc transporters [39], it does proffer a more direct relationship
with cadmium responsible for regulating SLC30A1 expression. This may reveal new insight as
to the role of cadmium in (bladder) cancer, where previously reported SLC30A1 and MT changes
may reflect increased concentrations of intracellular cadmium rather than zinc. Our demonstration
of differential MT-1 gene paralog induction by zinc and cadmium should help design future
(e.g., knockout) experiments to clarify the respective roles. Further experiments might also directly
quantify intracellular zinc in NHU cells after cadmium exposure and determine the consequences of
cadmium on zinc homeostasis and dysregulated cadmium-substituted proteins.
4. Materials and Methods
4.1. NHU Cell Culture and Exposure to Cadmium and Other Agents
Normal human urothelial (NHU) cells were obtained from the ureter/renal pelvis of patients
undergoing urological surgery, and maintained in vitro as nonimmortalized cell lines, as detailed
elsewhere [57,102]. For routine culture, NHU cells were grown as adherent monolayers on Primaria™
plasticware (BD Biosciences, Wokingham, UK) in low calcium [0.09 mM] keratinocyte serum-free
medium (KSFM) containing bovine pituitary extract and recombinant epidermal growth factor (Fisher
Scientific UK Ltd, Loughborough, UK) supplemented with 30 ng/mL cholera toxin (KSFMc). NHU
cell lines were subcultured by trypsinization at just-confluence and used in experiments between
passages 3–5.
For cadmium exposure, medium was replaced with fresh medium containing 10 µM cadmium
chloride (CdCl2). This concentration was selected after preliminary titration for toxicity (Figure 1A,B).
For other treatment agents, concentrations were selected following initial titration and target gene
expression assessment (Figure 3A,B).
Nonimmortalized NHU cell lines retain the capacity to differentiate to form a functional
tight barrier epithelium [58]. Differentiation was induced by switching NHU cells into medium
supplementedwith 5% adult bovine serum for 5 days before subculture onto semipermeable ThinCert™
(Greiner Bio-One Ltd., Stonehouse, UK) membranes with 0.4-µm pore size. After 24 h, the exogenous
calcium (Ca2+) concentration was increased to 2 mM (near physiological) and cultures were maintained
for a further 7–9 days to develop a tight barrier. For cadmium exposure of differentiated NHU cell
cultures, medium was removed from the apical chamber after establishment of a barrier >1000 Ω.cm2
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(see below) and replaced with fresh medium supplemented with 10 µM CdCl2, in order to mimic
apical exposure. RNA and protein were then harvested from these membranes for further analysis.
4.2. Measurement of Transepithelial Electrical Resistance
The barrier function of differentiated NHU cell sheets was assessed in triplicate cultures
by measuring the transepithelial electrical resistance (TEER) using an EVOM™ voltohmmeter
(World Precision Instruments, Hertfordshire, UK), as described [103]. A blank (no cell) membrane
measurement was subtracted from each TEER reading.
4.3. MT Transcript Abundance Quantification by Next-Generation Sequencing
mRNA-seq data for three donor-matched NHU cultured nondifferentiated and differentiated
samples were previously generated by our group [104]. Sequencing reads were ‘pseudoaligned’ to
the Ensembl v.91 human transcriptome (GRCh38.p10) using kallisto v0.44.0 [105] and relative gene
abundance was calculated as transcripts per million (TPM) following gene-level aggregation with
tximport v1.8.0 [106]. Differentiation-associated expression changes in the MT gene family were
detected by a differential expression analysis conducted by sleuth [107] accounting for matched-donor
samples. Differentially-expressed genes are reported with their log2 transformed fold change (log2FC)
and ‘q’ value (Benjamini–Hochberg correction).
4.4. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RT-PCR was performed to observe actual patterns of MT isoform induction (rather than relative
change). RNA was extracted from cells using TRIzol® (Fisher Scientific UK Ltd., Loughborough, UK)
and treated with a DNA-free™ kit (Ambion, supplied by Fisher Scientific UK Ltd., Loughborough,
UK). cDNA synthesis was performed on 1 µg RNA with random hexamers and the SuperScript®II
First-Strand Synthesis System (Fisher Scientific UK Ltd., Loughborough, UK). PCR primers were
designed specifically to detect all known splice variants for each MT-1 isoform gene, with GAPDH
used as the internal transcript control [108]. Primer sequences and optimized PCR conditions are
provided in Table 1. PCR was carried out in a T100 thermal cycler (Bio-Rad Services UK Ltd., Hemel
Hempstead Hertfordshire, UK) using 25 reaction cycles. Controls consisted of genomic DNA (gDNA
as template positive control), water (no template control), and no reverse transcriptase (gDNA negative
control). PCR products were separated on 2 % (w/v) agarose gels, stained using SYBR® Safe DNA gel
stain (Invitrogen supplied by Fisher Scientific UK Ltd., Loughborough, UK) and visualized on a Gene
Genius Gel Imaging System (Syngene, Cambridge, UK).
Table 1. Details of primers used for experiments.
Target Gene Forward or Reverse Sequence (5′–3′) Product Size (bp)
GAPDH Forward CAAGGTCATCCATGACAACTTTG 90
GAPDH Reverse GGGCCATCCACAGTCTTCTG 90
HMOX1 Forward CCAGCAACAAAGTGCAAGATTC 102
HMOX1 Reverse GTGTAAGGACCCATCGGAGAAG 102
MT-1A Forward CTCGAAATGGACCCCAACT 219
MT-1A Reverse ATATCTTCGAGCAGGGCTGTC 219
MT-1B Forward GGAACTCCAGGCTTGTCTTGG 77
MT-1B Reverse TTGCAGGAGGTACATTTG 77
MT-1E Forward TGCGCCGGCTCCTGCAAGTC 118
MT-1E Reverse ATGCCCCTTTGCAGACGCAGC 118
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Table 1. Cont.
Target Gene Forward or Reverse Sequence (5′–3′) Product Size (bp)
MT-1F Forward CCTGCACCTGCGCTGGTTCC 110
MT-1F Reverse ACAGCCCTGGGCACACTTGC 110
MT-1G Forward CTTCTCGCTTGGGAACTCTA 309
MT-1G Reverse AGGGGTCAAGATTGTAGCAAA 309
MT-1H Forward CCTCTTCTCTTCTCGCTTGG 317
MT-1H Reverse GCAAATGAGTCGGAGTTGTAG 317
MT-1M Forward CTAGCAGTCGCTCCATTTATCG 180
MT-1M Reverse CAGCTGCAGTTCTCCAACGT 180
MT-1X Forward GGACCCAACTGCTCCTGCTC 151
MT-1X Reverse TTTGCAGATGCAGCCCTGGGC 151
MT-2A Forward CCGACTCTAGCCGCCTCTT 259
MT-2A Reverse GTGGAAGTCGCGTTCTTTACA 259
MT-3 Forward AGTGCGAGGGATGCAAATG 98
MT-3 Reverse GCCTTTGCACACACAGTCCTT 98
SLC30A1 Forward GCATCAGTTTATGAGGCTGGTCCT 352
SLC30A1 Reverse CAGGCTGAATGGTAGTAGCGTGAA 352
4.5. Western Blotting
NHU cell cultures were lysed into electrophoresis sample buffer containing protease inhibitors and
sonicated. Twenty micrograms of protein was resolved on 4–12% Bis-Tris NuPage™ polyacrylamide
gels (Invitrogen) in 2-(N-morphilino) ethanesulfonic acid (MES) buffer and electro-transferred onto
polyvinylfluoride membranes (Millipore). Membranes were blocked with Odyssey® blocking buffer
(LI-COR Biotechnology OK Ltd., Cambridge, UK), incubated with primary antibodies for 16 h at 4 ◦C
and bound antibody detected using Alexa Fluor® 680-conjugated anti-mouse secondary antibody
(Invitrogen, Invitrogen supplied by Fisher Scientific UK Ltd., Loughborough, UK) or an IRDye
800-conjugated anti-rabbit secondary antibody (Tebu-Bio, Peterborough, UK). Antibody binding
was visualized using an Odyssey® Sa Infrared Imaging System (LI-COR®). Protein quantification was
performed using Odyssey® Image Studio™ software v5.0 (LI-COR®). Details of antibodies are given
Tables 2 and 3.
Table 2. Details of primary antibodies used for experiments.
Antigen Clone Host Supplier Dilution
Molecular
Weight (kDa)
Beta-actin A5441 Mouse Sigma Aldrich 1:10 000 (WB) 42
MT-1A B01P Mouse Abnova 1:750 (WB) 6
MT-1M 17281-AP Rabbit ProteinTech 1 µg/mL (WB) 6
Table 3. Details of secondary antibodies used for experiments.
Antigen Conjugate Host Supplier Application
Anti-mouse IgG Alexa 680 Goat Life Technologies WB
Anti-rabbit IgG Alexa 800 Goat Life Technologies WB
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5. Conclusions
MT-1 isoform expression has been characterized in normal human urothelium for the first time,
and a unique expression profile described with the use of isoform-specific antibodies. Individual
MT-1 genes demonstrated inducer-specific expression and two paralogs with cadmium-specific or
-selective induction were identified as candidate biomarkers of cadmium exposure. With the potential
for cadmium to interfere and substitute in the homeostatic regulation of zinc, new approaches are
proposed for understanding cadmium-induced nongenotoxic carcinogenesis.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/6/
1344/s1.
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